STOCK TITAN

Larimar Therapeutics Inc - LRMR STOCK NEWS

Welcome to our dedicated news page for Larimar Therapeutics (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Larimar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Larimar Therapeutics's position in the market.

Rhea-AI Summary
Larimar Therapeutics reports positive Phase 2 data for nomlabofusp in treating Friedreich's ataxia. The company raised $161.6 million in recent financing, extending its operating runway. Discussions with the FDA on accelerated approval for nomlabofusp are ongoing, with a BLA submission targeted for 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
earnings
-
Rhea-AI Summary
Larimar Therapeutics initiates an open label extension study for nomlabofusp in patients with Friedreich's ataxia, aiming to assess long-term safety and tissue frataxin levels. The company plans to use data from this study to support a potential BLA submission for accelerated approval by H2 2025, with initial data expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
-
Rhea-AI Summary
Larimar Therapeutics, Inc. announced its participation in the Leerink Partners Global Biopharma Conference to present and engage in investor meetings. The company's management team will be present on March 13, 2024, at 10 AM ET. A webcast link is provided for those interested, and a replay will be accessible on Larimar's website for 30 days post-presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
conferences
Rhea-AI Summary
Larimar Therapeutics, Inc. successfully closed a public offering of 19,736,842 shares of common stock, raising approximately $172.5 million. The proceeds will support the development of nomlabofusp (CTI-1601) and other pipeline candidates, as well as general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
Larimar Therapeutics, Inc. announces the pricing of its public offering, generating approximately $150.0 million. The company is focused on developing treatments for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.84%
Tags
offering
-
Rhea-AI Summary
Larimar Therapeutics, Inc. initiates a public offering of common stock and pre-funded warrants to support the development of pipeline candidates and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.84%
Tags
offering
Rhea-AI Summary
Larimar Therapeutics, Inc. announces positive Phase 2 data for nomlabofusp in Friedreich’s ataxia patients. The drug showed dose-dependent increases in frataxin levels in skin and buccal cells, with generally well-tolerated subcutaneous injections. The company plans an Open Label Extension study and aims for accelerated FDA approval by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
clinical trial
-
Rhea-AI Summary
Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported the completion of the full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial. The trial demonstrated no serious adverse events in either the CTI-1601 (nomlabofusp) or placebo groups. Top-line safety, pharmacokinetic, and frataxin data from Phase 2 are now expected in Q1 2024, with initiation of open label extension (OLE) trial on track for Q1 2024. Larimar also reported $95.6 million in cash, cash equivalents, and marketable securities as of September 30, 2023, providing projected cash runway into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.11%
Tags
earnings
-
Rhea-AI Summary
Larimar Therapeutics, Inc. will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York from November 6-7, 2023. The fireside chat will take place on November 7, 2023, from 1:10 - 1:40 PM ET. A replay of the chat will be available on Larimar's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
conferences
Rhea-AI Summary
Larimar Therapeutics appoints Jeffrey W. Sherman, M.D., F.A.C.P. to the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
management
Larimar Therapeutics Inc

Nasdaq:LRMR

LRMR Rankings

LRMR Stock Data

484.24M
32.55M
1.34%
83.55%
2.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bala Cynwyd

About LRMR

larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.